COVID-19. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 50 patients with COVID-19 will be included in this group and their treatment regimen includes oral Hydroxychloroquine (first day 400 mg/BD and from second day 200 m
Sponsors
Iran University of Medical Sciences
Presidential Transformation and Development Cooperation Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age equal or greater than 18 years Signing informed consent Diagnosis of COVID-19 by chest CT-scan or RT-PCR test
Exclusion criteria
Exclusion criteria: Respiratory failure People with a history of allergies to this drug and or a history of severe allergies Patients who used Arbidol (Tablets, capsules, granules) before hospitalization Women who are breastfeeding or pregnant Renal or liver function failure Anemia or thrombocytopenia Patient who received immunosuppressive drug during 3 months ago Congenital heart failure History of arrhythmia coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of patients fever. Timepoint: Measurement of patient's body temperature at the beginning of the study and 7 days after starting treatment. Method of measurement: Thermometer.;Measurement of complete blood count test. Timepoint: Performing a complete blood cell count test at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Determination of C-reactive protein test. Timepoint: Measurement of C-reactive protein level at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Chest CT Scan view symptoms. Timepoint: Patient's chest CT scan check at the beginning of the study and 30 days after starting treatment. Method of measurement: Taking a chest CT scan.;Measurement of blood oxygen saturation and no adjuvant oxygen therapy. Timepoint: Measurement of oxygen saturation level at the beginning of the study and 7 days after starting treatment. Method of measurement: Pulse oximeter.;Hospital admission days. Timepoint: check daily. Method of measurement: observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of erythrocyte sedimentation rate test. Timepoint: Measurement of erythrocyte sedimentation rate at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Observing virological results. Timepoint: Measurement of patient's sputum viral load at the beginning of the study and 7 days after starting treatment. Method of measurement: Real-time polymerase chain reaction test.;Patient death. Timepoint: Check daily. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Dr. Mitra Ranjbar
Iran University of Medical Sciences
Outcome results
None listed